Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) pioneers precision radiation therapy systems that redefine cancer treatment standards. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of radiation oncology.
Track all essential updates in one place, including earnings announcements, regulatory milestones, and technological breakthroughs related to flagship platforms like CyberKnife and Radixact. Our curated feed simplifies monitoring of partnership agreements, research collaborations, and market expansion efforts critical to understanding Accuray's position in medical technology.
Discover comprehensive coverage of operational updates, leadership changes, and product enhancements that impact clinical workflows and patient outcomes. The resource is designed to help stakeholders assess Accuray's progress in developing adaptive radiotherapy solutions with real-time tumor tracking capabilities.
Bookmark this page for streamlined access to verified information about ARAY, including innovation roadmaps and quality control certifications. Check regularly for objective reporting on developments influencing radiation oncology practices worldwide.
Accuray reported its Q2 fiscal 2023 results, highlighting net revenue of $114.8 million, a 1.3% decrease year-over-year, impacted by supply chain issues and a $6.1 million foreign exchange loss. Gross orders totaled $79.0 million, down 7.4% YoY, yet improved 13.2% sequentially, with a book-to-bill ratio above 1.2. The company incurred a GAAP net loss of $1.9 million versus a profit of $0.2 million in the previous year. However, adjusted EBITDA rose 24.1% to $8.5 million. Accuray also achieved notable achievements including an IMV Award for Best in Service in Radiation Oncology, with strong order growth in the Americas.
Accuray Incorporated (NASDAQ: ARAY) announced that the European Radiosurgery Center Munich has selected the CyberKnife S7™ System. This decision aims to enhance the Center's capabilities to treat a higher volume of patients requiring advanced radiosurgery treatments.
With nearly 18 years of experience, the Center has treated over 10,000 patients, emphasizing the system's precision for delivering focused radiation. The new installation will allow for a broader range of tumor types to be treated, minimizing the time required compared to conventional therapies. Accuray expresses gratitude for the Center's long-term collaboration, aiming for improved patient outcomes.
Accuray Incorporated (NASDAQ: ARAY) is set to release its financial results for the second quarter of fiscal year 2023, which ended on December 31, 2022. This announcement will occur after the market closes on February 1, 2023. Following the results, management will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the figures. Participants can join via provided dial-in numbers or listen in through a live webcast available on the Investor Relations section of their website.
Accuray (NASDAQ: ARAY) announced that Auckland Radiation Oncology (ARO) has become the first center in New Zealand to use the advanced CyberKnife S7™ System for precise cancer treatments. This system allows for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with high accuracy, often requiring only 1 to 5 outpatient sessions. The CyberKnife System enhances treatment efficiency, enabling ARO to treat more patients daily. CEO Suzanne Winter emphasized that this innovation broadens access to effective cancer care, while ARO’s Clinical Director Dr. Benji Benjamin noted the system’s potential to greatly improve treatment precision and minimize side effects.
Accuray Incorporated (NASDAQ: ARAY) will participate in the B. Riley Securities' 3rd Annual Oncology Conference on January 18-19, 2023. A virtual Fireside Chat is scheduled for January 18 at 7:00am PST/10:00am EST. The conference showcases over 30 healthcare companies and features discussions on innovative therapies and technologies in oncology. Attendees can access a live webcast on the Accuray website, with a replay available afterward. Accuray is dedicated to advancing radiation therapy solutions for cancer treatment.
Accuray Incorporated (NASDAQ: ARAY) reported its recognition for superior service in radiation oncology in the IMV ServiceTrak™ Radiation Oncology 2022 report, achieving the highest overall service performance scores in the industry. The company excelled in customer satisfaction, particularly in fields like service follow-up and field engineer competence. Customers praised Accuray's commitment to support and innovation. This marks the third consecutive year of increased customer repurchase intent for Accuray's radiation delivery systems, reflecting their dedication to quality and technological advancement.
Accuray (NASDAQ: ARAY) announced the installation of its second Radixact® System at the Oscar Lambret Center in Lille, France, enhancing cancer treatment capabilities. This system integrates ClearRT™ kVCT Imaging and Synchrony® technologies, improving treatment precision and versatility for various cancers. The Oscar Lambret Center, part of Unicancer, has a long history of utilizing Accuray technology. This partnership aims to deliver personalized, high-quality care, adapting to patient needs and medical conditions, ultimately increasing community treatment access.
Accuray Incorporated (NASDAQ: ARAY) reported Q1 fiscal 2023 results with net revenue of $96.5 million, down 10% year-over-year, affected by supply chain constraints and a $5.8 million foreign exchange hit. Gross orders were flat at $69.8 million, with a 6.5% increase on a constant currency basis. The GAAP net loss widened to $5.4 million, compared to a loss of $1.0 million last year. Adjusted EBITDA decreased to $1.9 million from $5.4 million. The company maintains its full-year guidance, highlighting strong demand for its precision radiation therapy solutions amidst ongoing challenges.
Accuray (NASDAQ: ARAY) has submitted the registration dossier for its Tomo® C radiation therapy system to China's National Medical Products Administration (NMPA). This milestone, shared during the Q4 FY2022 earnings call, aims to enhance access to radiation treatment for cancer patients in China. The Tomo C system is noteworthy as it is the first joint venture product made in China and addresses the growing demand for effective cancer therapies, with new cases projected to rise by 50% by 2040. Suzanne Winter, CEO, highlighted the expected growth in the Type B market, reinforcing Accuray's competitive edge.
Accuray Incorporated (NASDAQ: ARAY) announced that the CyberKnife® System has received reimbursement approval from Japan's Ministry of Health, Labor and Welfare for treating trigeminal neuralgia (TN). TN is a painful condition affecting the trigeminal nerve, impacting daily life significantly. The approval enables patients in Japan to access this innovative treatment, which offers a precision alternative to traditional methods. The CyberKnife System's unique technology allows for accurate radiation delivery in a single outpatient procedure, enhancing treatment options for the approximately 5,000 people affected by TN in Japan.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
